GT Biopharma Files 8-K for Material Agreement
Ticker: GTBP · Form: 8-K · Filed: Nov 21, 2024 · CIK: 109657
Sentiment: neutral
Topics: material-agreement, filing, financials
TL;DR
GT Biopharma signed a material deal on Nov 18, 2024. 8-K filed Nov 21.
AI Summary
GT Biopharma, Inc. filed an 8-K on November 21, 2024, reporting an entry into a material definitive agreement and financial statements. The filing date for the earliest event reported was November 18, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates GT Biopharma has entered into a significant agreement, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the nature of the agreement is not detailed in this summary.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- November 18, 2024 (date) — Date of earliest event reported
- November 21, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What is the nature of the material definitive agreement entered into by GT Biopharma, Inc. on November 18, 2024?
The provided text does not specify the details of the material definitive agreement.
What specific financial statements are being filed with this 8-K?
The filing indicates that financial statements are included, but the specific statements are not detailed in the provided text.
What is GT Biopharma, Inc.'s Standard Industrial Classification (SIC) code?
GT Biopharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was GT Biopharma, Inc. incorporated?
GT Biopharma, Inc. was incorporated in Delaware.
What were GT Biopharma, Inc.'s former company names and when did the name changes occur?
GT Biopharma, Inc. was formerly known as OXIS INTERNATIONAL INC (name change 19940916), DDI PHARMACEUTICALS INC (name change 19920703), and DIAGNOSTIC DATA INC /DE/ (name change 19850312).
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-11-21 09:25:39
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
- $2 million — urces, provides for up to approximately $2 million over the course of three years borne by
Filing Documents
- form8-k.htm (8-K) — 34KB
- ex10-1.htm (EX-10.1) — 165KB
- ex10-1_001.jpg (GRAPHIC) — 6KB
- ex10-1_002.jpg (GRAPHIC) — 6KB
- 0001493152-24-047085.txt ( ) — 412KB
- gtbp-20241118.xsd (EX-101.SCH) — 3KB
- gtbp-20241118_lab.xml (EX-101.LAB) — 33KB
- gtbp-20241118_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: November 21, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer